What type of study is this?

This is a Human Clinical Trial study (also classified as: Pre-Registered Trial).

What question did this study set out to answer?

To evaluate the efficacy and safety of itacitinib, an anti-JAK1 inhibitor, in adults with non-severe hemophagocytic lymphohistiocytosis (HLH).

December 8, 2025BloodOpen Access

View Full Paper

Ask AI

Bookmark

Authors

Phase II trial shows 71% response rate in non-severe HLH adults treated with itacitinib, suggesting effective use of anti-JAK1 agents.

To evaluate the efficacy and safety of itacitinib, an anti-JAK1 inhibitor, in adults with non-severe hemophagocytic lymphohistiocytosis (HLH).
Open-label, phase II study conducted across 23 French medical centers
Included adult patients meeting HLH diagnostic criteria and without severe organ failure
Primary endpoint: response rate at day 15, defined as complete or partial response based on clinical parameters.
35 patients were enrolled, with a response rate of 71% at day 15, exceeding the efficacy threshold
Of the responders, 15 achieved complete response and 10 partial response
The treatment was well tolerated, with only mild adverse effects and no grade ≥3 events reported.

Marc Michel (2025) studied this question.

View Full Paper

Ask AI

Bookmark

December 8, 2025BloodOpen Access

View Full Paper

Ask AI

Bookmark

Authors

Phase II trial shows 71% response rate in non-severe HLH adults treated with itacitinib, suggesting effective use of anti-JAK1 agents.

To evaluate the efficacy and safety of itacitinib, an anti-JAK1 inhibitor, in adults with non-severe hemophagocytic lymphohistiocytosis (HLH).
Open-label, phase II study conducted across 23 French medical centers
Included adult patients meeting HLH diagnostic criteria and without severe organ failure
Primary endpoint: response rate at day 15, defined as complete or partial response based on clinical parameters.
35 patients were enrolled, with a response rate of 71% at day 15, exceeding the efficacy threshold
Of the responders, 15 achieved complete response and 10 partial response
The treatment was well tolerated, with only mild adverse effects and no grade ≥3 events reported.

Marc Michel (2025) studied this question.

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark